Evaluating camrelizumab and apatinib mesylate for liver cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the efficacy and safety of a combination therapy using camrelizumab and apatinib mesylate in patients with unresectable hepatocellular carcinoma. It focuses on patients who meet specific clinical criteria and have measurable lesions, analyzing how this combination treatment can improve outcomes. The study is designed to provide insights into the potential benefits of this therapeutic approach in a real-world setting, contributing to the evolving treatment landscape for liver cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age: 18 years old ≤ age ≤ 75 years old, both male and female;
2. Strictly meet the clinical diagnostic criteria of the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer" (2022 Edition) or hepatocellular carcinoma patients diagnosed by histopathological or cytological examinations , and at least one measurable lesion (according to the mRECIST1.1 standard, the long diameter of the measurable lesion on spiral CT scan is ≥10mm or the short diameter of the malignant lymph node is ≥15mm);
3. Not previously accepted Patients with hepatocellular carcinoma who have progressed/intolerable and unresectable after systemic therapy or first-line systemic therapy;
4. CNLC stage IIb-IIIb;
5. Child-Pugh liver function grade A or B (5- 7 points);
6. ECOG PS score 0-1 points;
7. Expected survival period ≥ 12 weeks;
8. If the patient has active hepatitis B virus (HBV) infection: if HBV-DNA ≤ 2000, you can start directly Treatment; if HBV-DNA\>2000, antiviral treatment should be given for one week before starting treatment;
9. The subjects volunteered to join the study, had good compliance, and cooperated with follow-up.

Exclusion Criteria:

1. Pregnant or breastfeeding women;
2. Patients with contraindications to immunotherapy, including but not limited to the following: post-transplantation patients, patients with severe autoimmune diseases, patients with organ failure, patients who have previously experienced adverse reactions of grade 4 or above using immunotherapy, and uncontrolled infectious diseases;
3. Use immunosuppressive or systemic hormone therapy within 14 days before enrollment to achieve the purpose of immunosuppression (dose\>10mg/day prednisone or other equivalent hormones);
4. It has been confirmed that camrelizumab Patients who are allergic to injections, apatinib mesylate tablets and their excipients, or are allergic to other monoclonal antibodies;
5. Patients with impaired consciousness or inability to cooperate with treatment, combined with mental illness;
6. Patients who have participated in other clinical trials in the past three months;
7. Severe liver, kidney, heart, lung, brain and other major organ failure;
8. According to the investigator's judgment, patients with other serious concomitant diseases that endanger the patient's safety or affect the patient's completion of the study.

Where it's running

• Mengchao Hepatobiliary Hospital, Fujian Medical University
  Fuzhou, Fujian, China Recruiting

Study contacts

• Principal investigator: Yong yi Zeng — Mengchao Hepatobiliary Hospital, Fujian Medical University
• Study coordinator: Yong yi Zeng
• Email: lamp197311@126.com
• Phone: 13805083802

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining radiotherapy with camrelizumab and apatinib for liver cancer treatment

  This study is testing if a combination of radiation therapy with two medications can help shrink liver cancer tumors before surgery for patients whose cancer has spread to the portal vein.

  Recruiting Phase 2 Meng Chao Hepatobiliary Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06349317

• Combining cadonilimab and regorafenib for advanced liver cancer patients who didn't respond to previous treatment

  This study is testing if combining two drugs, cadonilimab and regorafenib, can help people with advanced liver cancer who didn't respond to earlier treatments.

  Recruiting Phase 2 Meng Chao Hepatobiliary Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06280105

• Combining camrelizumab and apatinib with TACE for liver cancer treatment

  This study is testing if combining two medications with a liver cancer treatment before surgery can help people with liver cancer live longer and have fewer problems after surgery.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05613478

• Surgery combined with immunotherapy and targeted therapy for advanced liver cancer

  This study is testing whether combining surgery with two treatments, camrelizumab and apatinib, can help people with advanced liver cancer live longer and feel better.

  Recruiting Phase 2/3 Guangxi Medical University · Nanning · NCT05062837

• VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs

  This study tests VRT106, with camrelizumab and apatinib, to see if it helps people with advanced hepatocellular carcinoma who have already had prior immune checkpoint inhibitors fail.

  Recruiting Phase 2/3 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589244

• Y-90 microspheres with camrelizumab and/or apatinib versus Y-90 alone or cTACE for unresectable liver cancer

  This trial will test whether adding camrelizumab and/or apatinib to Y-90 microsphere treatment helps people with unresectable, non-metastatic hepatocellular carcinoma more than Y-90 alone or conventional TACE.

  Recruiting at 2 sites Phase 2 GrandPharma (China) Co., Ltd. · Beijing and 2 other locations · NCT07334483

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.